RxDoctor Payments DataLook up a doctor →

Sanjay Sharma, MD

Medical Oncology · Fullerton, CANPI 1174609358

Payments from drug & device makers

$1,553,277in general payments, 2019–2025

Across 2,396 payments — averaging $648.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$579K
  • Exelixis Inc.$345K
  • EMD Serono, Inc.$133K
  • E.r. Squibb & Sons, L.L.C.$85K
  • Regeneron Healthcare Solutions, Inc.$66K
  • Merck$57K
  • plus $288K from 54 others
$25,032in research payments, 2019–2025

Across 4 payments — averaging $6258.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$25K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)221$578,510
Exelixis Inc.668$344,883
EMD Serono, Inc.93$133,199
E.r. Squibb & Sons, L.L.C.156$85,249
Regeneron Healthcare Solutions, Inc.70$66,268
Merck130$57,007
Amgen87$50,817
Eli Lilly6$48,128
Bristol Myers Squibb85$40,565
Sanofi46$39,332
Janssen Research & Development, LLC5$25,347
Pfizer68$24,140
Takeda Pharmaceuticals U.S.A., Inc.27$17,443
Array Biopharma Inc34$9,772
AbbVie42$6,154
Abbott85$4,332
Lilly USA, LLC54$2,715
Abiomed58$2,692
Johnson & Johnson(2 entities)57$2,528
Servier Pharmaceuticals LLC8$2,492
Jazz Pharmaceuticals Inc.4$1,967
Bayer19$1,315
Novartis58$1,169
Eisai Inc.17$869
Astellas Pharma US Inc32$634
Daiichi Sankyo Inc.26$541
Incyte Corporation20$495
Gilead(2 entities)22$493
Pharmacyclics LLC, An Abbvie Company32$475
Genentech USA, Inc.23$398
Karyopharm Therapeutics Inc.12$326
Boehringer Ingelheim11$265
Seagen Inc.11$260
Ipsen Biopharmaceuticals, Inc10$216
Blueprint Medicines Corporation7$214
Agios Pharmaceuticals, Inc.8$151
Deciphera Pharmaceuticals Inc.5$124
Myovant Sciences Inc.6$118
Caris MPI, Inc.1$115
Comsort, Inc1$100
Coherus Oncology, Inc.5$99
Rigel Pharmaceuticals, Inc.5$99
Blue Earth Diagnostics2$87
Geron Corporation2$83
Tesaro, Inc.4$82
Beigene USA, Inc.5$81
Puma Biotechnology, Inc.4$73
AMAG Pharmaceuticals, Inc.3$66
Verastem, Inc.4$53
GSK3$47
AVEO Pharmaceuticals, Inc.2$47
Sobi, Inc2$47
Medtronic1$40
Dova Pharmaceuticals2$40
Recordati_rare_diseases_inc.2$38
TG Therapeutics, Inc.2$36
Tolmar Pharmaceuticals, Inc.2$36
Foundation Medicine, Inc.2$34
Genmab U.S., Inc.1$32
Legend Biotech USA Inc.1$28

How this compares

$1,553,277 in reported general payments places this provider in the 80th percentile of 379 medical oncology providers in California.

See all medical oncology providers in California →

Medicare billing

Part B allowed, 2024
$132,713
Medicare patients
319
Services billed
995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Fullerton

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →